Bruce Y Lee1, Sarah M Bartsch, Shawn T Brown, Philip Cooley, William D Wheaton, Richard K Zimmerman. 1. *Public Health Computational and Operations Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD †Pittsburgh Supercomputing Center, Carnegie Mellon University ‡RTI International, Research Triangle Park, NC §University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
BACKGROUND: Influenza vaccination is administered throughout the influenza disease season, even as late as March. Given such timing, what is the value of vaccinating the population earlier than currently being practiced? METHODS: We used real data on when individuals were vaccinated in Allegheny County, Pennsylvania, and the following 2 models to determine the value of vaccinating individuals earlier (by the end of September, October, and November): Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based model (ABM), and FluEcon, our influenza economic model that translates cases from the ABM to outcomes and costs [health care and lost productivity costs and quality-adjusted life-years (QALYs)]. We varied the reproductive number (R0) from 1.2 to 1.6. RESULTS: Applying the current timing of vaccinations averted 223,761 influenza cases, $16.3 million in direct health care costs, $50.0 million in productivity losses, and 804 in QALYs, compared with no vaccination (February peak, R0 1.2). When the population does not have preexisting immunity and the influenza season peaks in February (R0 1.2-1.6), moving individuals who currently received the vaccine after September to the end of September could avert an additional 9634-17,794 influenza cases, $0.6-$1.4 million in direct costs, $2.1-$4.0 million in productivity losses, and 35-64 QALYs. Moving the vaccination of just children to September (R0 1.2-1.6) averted 11,366-1660 influenza cases, $0.6-$0.03 million in direct costs, $2.3-$0.2 million in productivity losses, and 42-8 QALYs. Moving the season peak to December increased these benefits, whereas increasing preexisting immunity reduced these benefits. CONCLUSION: Even though many people are vaccinated well after September/October, they likely are still vaccinated early enough to provide substantial cost-savings.
BACKGROUND: Influenza vaccination is administered throughout the influenza disease season, even as late as March. Given such timing, what is the value of vaccinating the population earlier than currently being practiced? METHODS: We used real data on when individuals were vaccinated in Allegheny County, Pennsylvania, and the following 2 models to determine the value of vaccinating individuals earlier (by the end of September, October, and November): Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based model (ABM), and FluEcon, our influenza economic model that translates cases from the ABM to outcomes and costs [health care and lost productivity costs and quality-adjusted life-years (QALYs)]. We varied the reproductive number (R0) from 1.2 to 1.6. RESULTS: Applying the current timing of vaccinations averted 223,761 influenza cases, $16.3 million in direct health care costs, $50.0 million in productivity losses, and 804 in QALYs, compared with no vaccination (February peak, R0 1.2). When the population does not have preexisting immunity and the influenza season peaks in February (R0 1.2-1.6), moving individuals who currently received the vaccine after September to the end of September could avert an additional 9634-17,794 influenza cases, $0.6-$1.4 million in direct costs, $2.1-$4.0 million in productivity losses, and 35-64 QALYs. Moving the vaccination of just children to September (R0 1.2-1.6) averted 11,366-1660 influenza cases, $0.6-$0.03 million in direct costs, $2.3-$0.2 million in productivity losses, and 42-8 QALYs. Moving the season peak to December increased these benefits, whereas increasing preexisting immunity reduced these benefits. CONCLUSION: Even though many people are vaccinated well after September/October, they likely are still vaccinated early enough to provide substantial cost-savings.
Authors: Ira M Longini; Azhar Nizam; Shufu Xu; Kumnuan Ungchusak; Wanna Hanshaoworakul; Derek A T Cummings; M Elizabeth Halloran Journal: Science Date: 2005-08-03 Impact factor: 47.728
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke Journal: Nature Date: 2006-04-26 Impact factor: 49.962
Authors: Jonathan M Raviotta; Kenneth J Smith; Jay DePasse; Shawn T Brown; Eunha Shim; Mary Patricia Nowalk; Richard K Zimmerman Journal: J Am Geriatr Soc Date: 2016-10-06 Impact factor: 5.562
Authors: Giovanna Elisa Calabro'; Elettra Carini; Alessia Tognetto; Irene Giacchetta; Ester Bonanno; Marco Mariani; Walter Ricciardi; Chiara de Waure Journal: Front Public Health Date: 2022-03-09
Authors: Jonathan M Raviotta; Kenneth J Smith; Jay DePasse; Shawn T Brown; Eunha Shim; Mary Patricia Nowalk; Angela Wateska; Glenson S France; Richard K Zimmerman Journal: Vaccine Date: 2017-09-07 Impact factor: 3.641
Authors: Wanitchaya Kittikraisak; Piyarat Suntarattiwong; Darunee Ditsungnoen; Sarah E Pallas; Taiwo O Abimbola; Chonticha Klungthong; Stefan Fernandez; Suchada Srisarang; Tawee Chotpitayasunondh; Fatimah S Dawood; Sonja J Olsen; Kim A Lindblade Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240
Authors: Bruce Y Lee; Jorge A Alfaro-Murillo; Alyssa S Parpia; Lindsey Asti; Patrick T Wedlock; Peter J Hotez; Alison P Galvani Journal: PLoS Negl Trop Dis Date: 2017-04-27
Authors: Nicola Luigi Bragazzi; Vincenza Gianfredi; Milena Villarini; Roberto Rosselli; Ahmed Nasr; Amr Hussein; Mariano Martini; Masoud Behzadifar Journal: Front Public Health Date: 2018-03-05
Authors: Sarah M Bartsch; Michael S Taitel; Jay V DePasse; Sarah N Cox; Renae L Smith-Ray; Patrick Wedlock; Tanya G Singh; Susan Carr; Sheryl S Siegmund; Bruce Y Lee Journal: Vaccine Date: 2018-10-16 Impact factor: 3.641